期刊文献+

早期诊断和优化治疗是改善结缔组织病相关肺间质病变预后的关键 被引量:4

原文传递
导出
摘要 结缔组织病相关肺间质病变(interstitiallungdi—seaseassociatedwithconnectivetissuedisease,CTD.ILD)不仅是结缔组织病(CTD)中常见的并发症,更是影响CTD患者预后不良的重要原因之一。近10年来的研究表明,不同的CTD中肺间质病变(ILD)的发生率不相同,不同的CTD合并ILD的病理类型也不同,不同的病理类型对药物的反应也不同。例如在硬皮病,合并ILD的发病率最高达45%,病理以寻常型或非特异性间质性肺炎为主,激素反应差;而系统性红班狼疮合并ILD较低(约为2%~8%),病理分型以急性间质性肺炎多见,激素反应相对较好。
作者 张晓
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2012年第3期145-146,共2页 Chinese Journal of Rheumatology
  • 相关文献

参考文献10

  • 1Saketkoo LA, Matteson EL, Brown KK. Developing disease activity and response criteria in connective tissue disease-related interstitial lung disease. J Rheumatol, 2011, 38: 1514-1518.
  • 2Castelino FV, Varga J. Interstitial lung disease in connective tis- sue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther, 2010, 12: 213-216.
  • 3Hamblin MJ, Horton MR. Rheumatoid arthritis-associated inter- stitial lung disease: diagnostic dilemma. Pulm Med, 2011, 2011 : 872120.
  • 4Kreider ME, Hansen-Flaschen J, Ahmad NN, et al. Compli- cations of video-assisted thoracoscopic lungbiopsy in patients with interstitiallung disease. Ann Thorac Surg, 2007, 83 : 1140-1144.
  • 5Tourkina E, Bonner M, Oates J, et al. Altered monocyte and fihrocyte phenotype and function in scleroderma interstitial lung dnisease: reversal by caveolin-1 scaffolding domain peptide. Fi- brogenesis Tissue Repair, 2011, 4: 15-18.
  • 6Wanchu A, Suryanaryana BS, Sharma S, et al. High-dose pre- disolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study. Int J Rheum Dis, 2009, 12: 239-242.
  • 7Domiciano DS, Bonfa E, Borges CT, et al. A long-term prospec- tive randomized controlled study of non-specific interstitial pneu- monia (NSIP) treatment in scleroderma. Clin Rheumatol, 2011, 30 : 223-229.
  • 8Khanna D, Saggar R, Mayes MD, et al. A one year, phase I / ]I a open-label pilot trial of imatinib mesylate (Gleevec) in the treatment of systemic sclerois associated active interstitial lung disease (SSc-ILD). Arthritis Rheum, 2011, 63: 3540-3546.
  • 9Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curt Opin Pulm Med, 2011, 17: 362-367.
  • 10Trachtman H, Fervenza FC, Gipson DS, et al. A phase 1, sing- le-dose study of fresolimumab, an anti-TGF-15 antibody, in treat- ment resistant primary focal segmental glomerulosclersis. Kid Int, 2011, 79: 1236-1243.

同被引文献21

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部